Press Release, Lund May 12, 2020 A patent licensing agreement has been signed between Hamlet Pharma AB and Linnane Pharma AB to secure the development…
Read More
Newsletter 2020 – Issue 2; Business Update – Hamlet Pharma receives EU grant for €2.2M Last month, members of the Hamlet Pharma Executive Team travelled…
Newsletter 2020 – Issue 1; Bladder Cancer “Bladder cancer (BC) has the highest lifetime treatment costs per patient (pp) of all cancers, followed by colorectal-,…
Press Release, Lund February 5, 2020 Alpha1H shows significant promise as a new and effective cancer drug with low toxicity in a clinical bladder cancer…
Pressmeddelande, Lund 3 februari, 2020 Hamlet Pharma tillförs 12,95 miljoner SEK genom inlösen av teckningsoptioner utfärdade i samband med den riktade emissionen från den 1…
Dose-escalation studies have been performed to find the optimal dose of Alpha1H for future therapeutic studies. In the murine bladder cancer model, we observed a…
The Board of Hamlet Pharma AB has decided on a new date for the Annual General Meeting. The new date of the Annual General Meeting is Thursday,…
With Hamlet,from breast milk and the “foundation of life”to cancer therapy that improves the quality of life World Breastfeeding Week 2018 begins today, a worldwide,…
HAMLET Pharma has formally appointed Prof Catharina Svanborg, Chairman and founder of HAMLET Pharma, as Chief Medical Officer (CMO), to enable her to continue her…
HAMLET Pharma AB is pleased to announce that we have received a notification from the European Patent Office (EPO) regarding a patent application with claims…
Hamlet Pharma takes a further step towards the start of the clinical study in patients with bladder cancer. The company has received ethical approval of…
Hamlet Pharma announces that the production of the Alpha1H peptide has been successful and that the peptide is ready for delivery. The peptide meets the…